Zobrazeno 1 - 10
of 149
pro vyhledávání: '"tumour microenvironment (tme)"'
Autor:
Vladan Milosevic, Arne Östman
Publikováno v:
Upsala Journal of Medical Sciences, Vol 129, Pp 1-12 (2024)
Cancer-associated fibroblasts (CAFs) are a heterogeneous cell population recognized as a key component of the tumour microenvironment (TME). Cancer-associated fibroblasts are known to play an important role in maintaining and remodelling the extracel
Externí odkaz:
https://doaj.org/article/49576ea65a9b4a4c971364719cff2b1b
Autor:
Zizhuo Li, Anqi Lin, Zhifei Gao, Aimin Jiang, Minying Xiong, Jiapeng Song, Zaoqu Liu, Quan Cheng, Jian Zhang, Peng Luo
Publikováno v:
Clinical and Translational Medicine, Vol 14, Iss 7, Pp n/a-n/a (2024)
Abstract Background and main body The anti‐tumour and tumour‐promoting roles of B cells in the tumour microenvironment (TME) have gained considerable attention in recent years. As essential orchestrators of humoral immunity, B cells potentially p
Externí odkaz:
https://doaj.org/article/7932b3d021244cff9e56e21bc52d6714
Autor:
Zeli Yin, Liming Wang
Publikováno v:
Annals of Medicine, Vol 55, Iss 1, Pp 1058-1069 (2023)
AbstractTumour-associated endothelial cells (TECs) are a critical stromal cell type in the tumour microenvironment and play central roles in tumour angiogenesis. Notably, TECs have phenotypic plasticity, as they have the potential to transdifferentia
Externí odkaz:
https://doaj.org/article/e9aa2ac6a6c64368a587bd1601cac218
Autor:
Raquel García-Vílchez, Ana M. Añazco-Guenkova, Sabine Dietmann, Judith López, Virginia Morón-Calvente, Silvia D’Ambrosi, Paz Nombela, Kepa Zamacola, Isabel Mendizabal, Saioa García-Longarte, Amaia Zabala-Letona, Ianire Astobiza, Sonia Fernández, Alejandro Paniagua, Borja Miguel-López, Virginie Marchand, Diego Alonso-López, Angelika Merkel, Ignacio García-Tuñón, Aitziber Ugalde-Olano, Ana Loizaga-Iriarte, Isabel Lacasa-Viscasillas, Miguel Unda, Mikel Azkargorta, Félix Elortza, Laura Bárcena, Monika Gonzalez-Lopez, Ana M. Aransay, Tomás Di Domenico, Manuel A. Sánchez-Martín, Javier De Las Rivas, Sònia Guil, Yuri Motorin, Mark Helm, Pier Paolo Pandolfi, Arkaitz Carracedo, Sandra Blanco
Publikováno v:
Molecular Cancer, Vol 22, Iss 1, Pp 1-36 (2023)
Abstract Newly growing evidence highlights the essential role that epitranscriptomic marks play in the development of many cancers; however, little is known about the role and implications of altered epitranscriptome deposition in prostate cancer. He
Externí odkaz:
https://doaj.org/article/23776f080b2242829817059af1fa8867
Publikováno v:
Cells, Vol 13, Iss 12, p 1057 (2024)
Diffuse large B cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma worldwide, constituting around 30–40% of all cases. Almost 60% of patients develop relapse of refractory DLBCL. Among the reasons for the therapy failure, tumour
Externí odkaz:
https://doaj.org/article/52caac3063614bb598260447be1ac577
Autor:
Runzhi Huang, Zehui Sun, Shuyuan Xian, Dianwen Song, Zhengyan Chang, Penghui Yan, Jie Zhang, Huabin Yin, Zixuan Zheng, Peng Hu, Zhenyu Li, Dan Huang, Yihan Liu, Chenyang Jiang, Man Li, Siqi Li, Tong Meng, Daoke Yang, Zongqiang Huang
Publikováno v:
Annals of Medicine, Vol 54, Iss 1, Pp 1918-1937 (2022)
Background Toll-like receptors (TLRs) are important components of the innate and adaptive immune systems, and abnormal TLR expression has been linked to a variety of cancers. However, there was a lack of clarity on the association of TLR stimulation
Externí odkaz:
https://doaj.org/article/d022c7f1e5f64935a8c14fcf6c47299b
Publikováno v:
Frontiers in Pharmacology, Vol 14 (2023)
Externí odkaz:
https://doaj.org/article/4eb40e2b842a4044b78d006434025e0c
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Ulrich Sommer, Celina Ebersbach, Alicia-Marie K. Beier, Gustavo B. Baretton, Christian Thomas, Angelika Borkowetz, Holger H. H. Erb
Publikováno v:
Frontiers in Molecular Biosciences, Vol 9 (2022)
Immune checkpoint inhibitors have become a promising new therapy for cancer treatment. However, due to prostate cancer’s high heterogeneity and immune-suppressive tumour microenvironment, clinical trials with immune checkpoint inhibitors for prosta
Externí odkaz:
https://doaj.org/article/1772f66307de4de6821c29ea8328f328
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
The tumour microenvironment (TME) presents a major block to anti-tumour immune responses and to effective cancer immunotherapy. The inflammatory mediators such as cytokines, chemokines, growth factors and prostaglandins generated in the TME alter the
Externí odkaz:
https://doaj.org/article/e73fac2e64be48678ef36b2b4853e467